Sep 2, 2026 · 18 min
GLP-1 drugs push Big Food beyond indulgence
How Big Food Is Navigating the GLP-1 Era
As GLP-1 users eat less and seek more protein and fiber, food companies must adapt products without abandoning the broader market for traditional snacks.
- 1GLP-1 drugs are reducing cravings and reshaping demand for salty snacks, baked goods, and other indulgent foods.
- 2Companies are testing higher-protein, higher-fiber recipes and packaging claims while confronting the technical limits of satisfying reformulated products.
- 3Data and AI tools are helping food makers model GLP-1 consumers as they build a playbook for a potentially lasting shift.
Don't miss
The episode reveals that General Mills created an AI persona named Lisa to represent a GLP-1 user during product development.
The brief
At a Conagra test kitchen, chefs evaluate packaged breakfast foods for satisfaction, offering a close-up view of how GLP-1 drugs are changing product development.
GLP-1 users may feel less hunger, fewer cravings, and altered taste, putting pressure on a food model built around sugar, salt, and indulgence.
The shift reaches beyond individual users: households are seeking more protein, fiber, and fresher foods while companies test claims and reformulations that still taste satisfying.
General Mills is using AI personas, including a fictional GLP-1 user named Lisa, alongside purchasing and social-media data to speed product decisions.
Executives see GLP-1s as more durable than past diet trends, but the emerging playbook keeps high-fat, high-salt, and high-sugar products for consumers who still want them.